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Abstract
Classically, G protein-coupled receptors (GPCRs) are thought to activate G protein from the 
plasma membrane and are subsequently desensitized by β-arrestin (βarr). However, some GPCRs 
continue to signal through G protein from internalized compartments, mediated by a GPCR–G 
protein–βarr ’megaplex’. Nevertheless, the megaplex’s molecular architecture remains unknown. 
Here, we present its cryo-electron microscopy structure, which shows simultaneous engagement of 
human G protein and bovine βarr to the core and phosphorylated tail, respectively, of a single 
active human chimeric β2-adrenergic receptor with the C-terminal tail of the arginine vasopressin 
type 2 receptor (β2V2R). All three components adopt their canonical active conformations, 
suggesting that a single megaplex GPCR is capable of simultaneously activating G protein and 
βarr. Our findings provide a structural basis for GPCR-mediated sustained, internalized G protein 
signaling.
G protein coupled receptors (GPCRs) are a class of ubiquitous cell-surface receptors 
involved in the regulation of many physiological processes1,2. An agonist stabilizes a GPCR 
in an active conformation, which facilitates binding and activation of G proteins. This leads 
to generation of second messenger molecules like cyclic AMP (cAMP) and subsequent 
signal propagation. In order to terminate G protein signaling, GPCR kinases (GRKs) 
phosphorylate the receptor, often on its C-terminal tail, which enables binding of β-arrestin 
(βarr) to the receptor1,3. βarr interacts with both the phosphorylated GPCR tail and 
intracellular core, with the latter interaction sterically blocking G protein binding and 
desensitizing further G protein signaling. βarr promotes internalization of the receptor by 
recruiting endocytic proteins (Fig. 1)3,4. Subsequently, the receptor is either: 1) rapidly 
recycled to the plasma membrane for receptors that transiently interact with βarr (class A 
GPCRs) or 2) internalized into endosomes followed by degradation for receptors that 
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strongly interact with βarr (class B GPCRs)4,5. βarr is also capable of mediating G protein-
independent signaling pathways by scaffolding other signaling proteins3.
Recently, class B GPCRs such as the thyroid-stimulating hormone receptor, parathyroid 
hormone receptor and the vasopressin type 2 receptor (V2R) have been reported to engage in 
sustained G protein signaling after receptor internalization into endosomes rather than being 
desensitized6–9. Internalized G protein signaling has been difficult to incorporate within the 
‘classical understanding’ of GPCR biology, since the GPCR–βarr interaction which drives 
internalization was thought to sterically block G protein binding and desensitize further 
signaling. However, we demonstrated that GPCR–βarr complexes can assume two distinct 
conformations with βarr either: (1) only bound to the phosphorylated receptor C-terminal 
tail and appears to hang from the receptor (‘tail conformation’); or (2) also bound 
concurrently to the receptor intracellular core via its finger loop region (‘core 
conformation’)9–11. In the tail conformation, the receptor intracellular core is presumably 
exposed, potentially allowing for interaction with G protein to form a GPCR–G protein–βarr 
‘megaplex’ capable of stimulating G protein signaling while being internalized by βarr (Fig. 
1, black box)9.
The megaplex hypothesis is supported by the observation that megaplex components come 
into close proximity with each other at endosomes for many class B GPCRs using cellular 
bioluminescence resonance energy transfer (BRET) assays6,8,9,12–14. Additionally, we 
previously demonstrated that functional megaplexes can be formed in vitro in an agonist-
dependent manner, and the GPCRs within these megaplexes activate G proteins by 
promoting GTPase activity, GTP/GDP exchange and dissociation of the Gα subunit from 
Gβγ subunits9.
That a GPCR within a megaplex can elicit both G protein and βarr functions (i.e. 
internalization) raises a number of questions: what is the conformation of a GPCR when 
simultaneously bound to both G protein and βarr? What are the conformations of the 
megaplex βarr and G protein, and how do these conformations compare to the canonical 
active conformations they each separately adopt? To answer these questions and understand 
the structural basis for megaplex-mediated signaling by internalized GPCRs, we here report 
a cryo-electron microscopy (cryo-EM) structure of the megaplex.
Results
Complex Formation and Structure Solution
To form megaplexes, we first purified the β2V2R–βarr complex co-expressed with a 
prenylated GRK2 (GRK2-CAAX) bound to the high-affinity β2-adrenergic receptor (β2AR) 
agonist BI-167107 (BI) and stabilized by the conformationally sensitive antibody fragment 
Fab3010. Gs protein was added to the β2V2R–βarr1–Fab30 complex to form the megaplex 
along with nanobody 35 (Nb35) to stabilize the β2V2R–Gs interaction (Extended Data Fig. 
1)9,15. The β2V2R is an N-terminal T4 lysozyme (T4L)-fused, modified β2AR with the first 
341 residues of the β2AR combined with the last 29 amino acids V2R C-terminal tail 
(V2T)10. While maintaining the pharmacological properties of the β2AR, the β2V2R 
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interacts strongly with βarrs, forming megaplexes and promotes endosomal G protein 
signaling comparable to the class B V2R4,5,9–11.
Initial cryo-EM imaging revealed significant dissociation of the megaplex, with class 
averages from the few intact megaplex particles displaying preferential orientation and 
blurred density for the βarr1–Fab30 portion, presumably due to its flexibility (Extended 
Data Fig. 2). To improve complex stability, we formed the megaplex with Nanobody 32 
(Nb32), which further stabilizes active βarr1 bound to the phosphorylated V2T11. Nb32 
substantially enhanced the number of intact megaplex particles and led to better-defined 
density for βarr1–Fab30 in class averages, potentially by sterically limiting βarr1–Fab30 
flexibility (Extended Data Fig. 2). To overcome preferential orientation, all data were 
subsequently collected with the specimen stage tilted from 30° to 50° (Extended Data Figs. 
3,4).
Our initial reconstruction of the megaplex shows Gs binding to the β2V2R intracellular core, 
while βarr1 binds to the phosphorylated V2T in a tail conformation (Extended Data Fig. 5). 
We do not observe additional contact between βarr1 and the receptor, nor any direct contact 
between Gs and βarr1 (Extended Data Fig. 5). We observe Nb32 binding to the N-terminal 
lobe of βarr1, and that it sterically makes contact with the β2V2R and Nb35 at low map 
thresholds (Extended Data Fig. 5).
The phosphorylated receptor C-terminal tail serves as the only connection between the 
receptor and βarr1. Because this connection is inherently flexible, our structure’s local 
resolution is limited to ~7 Å (Extended Data Figs. 5,6). Subsequent attempts to reconstruct 
the megaplex after computationally subtracting Fab30 and Nb32 densities led to a map with 
well-defined features for the β2V2R–Gs–Nb35 portion, but not for the smaller βarr1 bound 
to the phosphorylated tail, indicating that βarr1 is truly flexible relative to the β2V2R–Gs–
Nb35 component (Extended Data Fig. 4).
To overcome this inherent flexibility, we analyzed the megaplex as two separate 
subcomplexes: the BI–β2V2R–Gs–Nb35 (with T4L removed) and the Nb32–V2T–βarr1–
Fab30 subcomplexes, from this point on referred to as the β2V2R–Gs and βarr1–V2T 
subcomplexes, respectively. By realigning each subcomplexes separately, we obtained 
reconstructions for the β2V2R–Gs and βarr1–V2T subcomplexes at 3.8 Å and 4.0 Å, 
respectively (Table 1, and Extended Data Figs. 4, 6, 7). While the subcomplexes’ resolution 
vary directionally, the higher resolution allows for analysis of all relevant megaplex 
interactions. These subcomplex reconstructions are aligned to the overall reconstruction and 
displayed together as a composite cryo-EM map (Fig. 2a,b).
The β2V2R–Gs portion of the megaplex
The Gs protein engages the β2V2R at its intracellular core (Fig. 3a). To assess the megaplex 
β2V2R conformation, we compared it to the structures of inactive, carazolol-bound β2AR 
(PDB: 2RH1) and the active, Gs protein-bound β2AR (PDB: 3SN6)15,16. In comparison to 
the inactive β2AR structure, the megaplex β2V2R shows a 15Å outward shift away from the 
receptor intracellular core in its transmembrane (TM) helix 6, as measured from the Cα of 
residue E2686.30 (superscript denotes Ballesteros-Weinstein numbering)17. TM5 displays an 
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outward movement of 3 Å, as measured from the Cα of L2305.69. TM3 and TM7 move 
inward towards the intracellular core by 2 Å (as measured from T1363.55) and 5 Å (as 
measured from C3277.54), respectively (Fig. 3b). These changes are consistent with those 
observed in the active, Gs-bound β2AR15. The Gs-bound β2AR and our β2V2R are nearly 
superimposable, with a Cα RMSD of 0.63 Å (Fig. 3c). Examination of the ligand binding 
pocket reveals density that can be attributed to BI, which adopts a similar binding pose to 
those in previous crystal structures of BI-occupied β2AR bound to G protein-mimicking 
nanobodies (Fig. 3d, and Extended Data Fig. 8a)18,19.
Analysis of the β2V2R–Gs interaction surface revealed contacts mostly between the α5 helix 
on Gαs and TM3, TM5, TM6, and intracellular loop 2 (ICL2), consistent with those 
observed in the β2AR–Gs crystal structure (Fig. 3e). The Gαs α5 helix forms primarily 
nonpolar interactions with various residues located in TM5 and TM6 (Fig. 3e, and Extended 
Data Fig. 8b). Polar residues on TM5 of the receptor, namely E2255.64, Q2295.68, and 
K2325.71, are within distance to form a hydrogen bonding network with Gαs residues D381 
and Q384. Also notable is the nonpolar interaction formed between F13934.51 in ICL2 with 
the hydrophobic pocket formed by V217, F219, and F376 of Gαs (Fig. 3e, and Extended 
Data Fig. 8b). Significant interactions involving the DRY motif, namely packing of Y391 of 
the Gαs α5 helix against R1313.50 as well as the hydrogen bonding network between 
Y14134.53, T682.39, and D1303.49 is also observed (Fig. 3e, and Extended Data Fig. 8b).
In the presence of the tail-bound βarr1, when our β2V2R–Gs and the β2AR–Gs complex 
were aligned by their receptors, a 3.4° rotation in Gβγ around an axis parallel to the 
membrane was observed, and a 3° rotation in Gαs was observed around an axis parallel to 
the β2V2R–Gαs contact compared to the β2AR–Gs crystal structure (Fig. 3f). Taken 
together, while G protein adopts a distinct rotational pose, the overall receptor conformation 
and key receptor–Gs interactions appear to be unchanged, suggesting canonical G protein 
activation by a megaplex GPCR.
The βarr1–V2T portion of the megaplex
The βarr1–V2T subcomplex shows V2T binding to the N-terminal lobe of an active βarr1, 
indicated by a ~20° twist between its N and C-terminal lobes (Fig. 4a). Fab30 and Nb32 
concurrently interact with various regions of βarr1 as well as the V2T; Fab30 forms 
hydrogen bonds with phosphorylated residues S362 (pS362) while Nb32 forms electrostatic 
interactions with pS363 and pS364 on the V2T (Extended Data Fig. 9a,b). The direct 
interactions of Fab30 and Nb32 with the V2T provide an explanation for the conformational 
selectivity of these stabilizers for active βarr.
Previously, we reported a crystal structure of a Fab30-stabilized βarr1 bound to a synthetic 
V2R phosphopeptide (V2Rpp), which acts as a phosphorylated receptor C-terminal tail 
mimic20. The V2Rpp is derived from the last 29 amino acids of the V2R and contains eight 
chemically synthesized potential phosphorylated serines and threonines at positions pT347, 
pS350, pS357, pT359, pT360, pS362, pS363, and pS364. However, our structure shows only 
six GRK2-phosphorylated residues on the V2T that interact with βarr1: pS357, pT359, 
pT360, pS362, pS363, and pS364 (Fig. 4b,c and Extended Data Fig. 10a).
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All of these phosphorylated residues with the exception of pT359 form electrostatic 
interactions with lysines and arginines lining the surface of the N-terminal lobe of βarr1. 
Residue pT359 points outward and does not appear to make any contact with βarr1 (Fig. 
4b). More specifically, residues pS357 and pS363 make electrostatic interactions with the 
well-conserved βarr1 residues K11 and K10 within β-strand I of βarr1, respectively (Fig. 
4b). In addition, both pS363 and pS364 appear to interact with K107 on α-helix I of βarr1, 
while pS362 is positioned to interact with R7 (Fig. 4c). Finally, pT360 is well-positioned to 
interact with R25 and K294. These interactions are comparable with interactions previously 
reported between the V2Rpp and βarr120.
A comparison between the βarr1–V2T subcomplex and the V2Rpp–βarr1–Fab30 crystal 
structure illustrates that while βarr1 in both structures adopts a similar active conformation 
(Cα RMSD of 0.76Å), the structure with V2Rpp contains interaction between pS347 and 
pT350 not observed in our structure (Fig. 5a). pS347 interacts extensively with residues on 
βarr1 near the finger loop’ region, forming ionic interactions with R65 and K77 and 
participates in hydrogen bonding with Y63. Similarly, pT350 forms electrostatic interactions 
with R62, K138, and R165 on βarr1 (Fig. 5a, inset).
To gain further insight into which serine and threonine residues on the V2T are 
phosphorylated upon receptor stimulation, we performed liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) on unstimulated β2V2R expressed by itself and BI-
stimulated β2V2R co-expressed with GRK2-CAAX (Extended Data Fig. 10b). Our analysis 
revealed that T347, S350, S363, and S364 are phosphorylated in both samples, whereas 
S357, T359, T360, and S362 are only phosphorylated after receptor stimulation. These data 
suggest that: (1) T347/S350 are phosphorylated independent of stimulation, potentially 
through a GRK-independent mechanism and are not critical for βarr1 binding, (2) 
phosphorylation at residues S357, T359, T360, and S362 are necessary to recruit and 
stabilize βarr1 interaction with the V2T.
Finally, from our EM map, we observe an additional interaction between two acidic V2T 
residues D355 and E356 with βarr1, not observed in the V2Rpp–βarr1–Fab30 crystal 
structure (Fig. 4c). While local resolution does not allow for placement of side chains for 
D355 and E356, cryo-EM density for this region suggests that they are in position to interact 
with K160 and R161 on βarr1. Interestingly, these two acidic residues are prevalent in the C-
terminal tail of a number of GPCRs (e.g. β2AR, rhodopsin, and vasopressin receptors) and 
have been proposed to form a consensus motif for GRK1 and GRK2 phosphorylation, which 
when mutated in the closely-related vasopressin 1a receptor led to a loss in all tail 
phosphorylation21.
In order to further understand the structural implications of GPCR–arrestin interaction, we 
compared our βarr1–V2T portion of the megaplex, which binds to the β2V2R in a tail 
conformation, to the rhodopsin-visual arrestin crystal structure, in which visual arrestin 
binds the intracellular core of rhodopsin in addition to the phosphorylated tail (Fig. 5b). 
Alignment of βarr1 and visual arrestin in these two structures show that V2T residues 
pS357, pT360, pS363 align well with residues pT336, pS338, and E341 on the rhodopsin 
tail. In addition, our structure has three additional phosphorylation sites, at positions pT359, 
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pS362, and pS364 (Fig. 5b). All of these additional sites, with the exception of pT359, 
interact with βarr1, most likely conferring higher receptor affinity to βarr1 even though a 
smaller number of phosphorylated residues on a GPCR tail may be sufficient to activate 
arrestin.
Architecture of the megaplex within a cell membrane
We noted that βarr1 in our megaplex structure is pointing upward towards an area where the 
membrane is located in a cellular context. This position of βarr1 is facilitated by a physical 
clash between the receptor, Nb35 and Nb32, both of which are needed to stabilize the 
complex, and the lack of a membranous barrier in our detergent-purified megaplex 
(Extended Data Fig. 5). Therefore, we employed coarse-grained molecular dynamics (MD) 
simulation to explore the movement of βarr1 when bound to the highly flexible receptor C-
terminal tail within the megaplex in a cellular environment.
We modeled the entire megaplex embedded within a dipalmitolphosphatidylcholine (DPPC) 
bilayer in the absence of all protein stabilizers (Fig. 6a). As expected, βarr1 movement is 
much more constrained when a lipid bilayer is present. Moreover, the two proline residues 
348 and 349 induces a kink in the V2T, thus serves to restrict βarr1 distance from the 
β2V2R–Gs portion. Even though these two factors limit the βarr1 range of motion, it can still 
adopt a wide range of possible conformations. To sample this conformational range, we 
modeled three possible megaplex structures, each of them different by the position of βarr1–
V2T in relation to the β2V2R–Gs portion and the membrane (Fig. 6a, MD runs 1–3). A 30 ns 
coarse-grained MD simulation was run using each modeled structure as a starting point (Fig. 
6b). In all three MD runs, βarr1 flexibly moves in relation to the β2V2R–Gs subcomplex. 
Interestingly, in runs 1 and 3, nonpolar βarr1 residues 332GGLLG336, part of a loop at the 
distal edge of the C-terminal lobe, make transient contacts with the lipid bilayer at various 
time points (Fig. 6b, black circles). Another βarr1 C-terminal loop, comprising residues 
261TVAPS265, also makes contact with the membrane, albeit to a lesser extent. Previous MD 
experiments as well as the rhodopsin-visual arrestin crystal structure (in which visual 
arrestin binds both the phosphorylated C-terminal tail and core of rhodopsin) have both 
shown that various analogous loops in visual arrestin can interact with a lipid bilayer22,23. 
Our results indicate that a tail-bound βarr1 in a megaplex has the ability to maintain this 
interaction, and further highlight the diverse positions that βarr1 could adopt within the cell 
membrane as part of the megaplex.
The ability of β2V2R to interact with and activate Gs while being bound to βarr1 through the 
flexible C-terminal tail in a cellular context was further confirmed using βarr1/βarr2/β2AR 
triple knock-out HEK293 cells transiently expressing functionally verified β2V2R–βarr1 or 
β2V2R–βarr2 fusion proteins9,11. In these cells, BI-stimulation of β2V2R–βarr1/2 resulted in 
a fast and sustained increase in cAMP comparable to either β2V2R alone or forskolin-
stimulated cAMP production (Fig. 6c). These results demonstrate that a single GPCR 
residing within a cell membrane and while being coupled functionally to βarr (in this case 
through a covalent attachment) can still physically interact with and activate G protein.
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Discussion
The initial discovery of βarrs provided a mechanism for how GPCR-mediated G protein 
signaling is desensitized24,25. Overlapping binding sites of G proteins and βarrs at the 
receptor core have been confirmed in multiple structural studies, and therefore, it has 
traditionally been assumed that binding of G protein and βarr to a single receptor are 
mutually exclusive15,23–28.
However, the discovery that a class B GPCR–βarr complex in the tail conformation can 
continue to activate G protein through the formation of megaplexes provides a biophysical 
explanation for the ability of some GPCRs to signal within internalized cellular 
compartments. Now, we show in our megaplex structure that the BI-bound, active β2V2R 
binds to Gs protein at the receptor intracellular core while coupling to βarr1 via the 
phosphorylated V2T (Fig. 2). The β2V2R–Gs contacts in the megaplex are also comparable 
to those of the β2AR–Gs structure, indicating that Gs protein is being activated by the 
megaplex receptor in a canonical fashion (Fig. 3e). The V2T -bound βarr1 also adopts an 
active conformation, indicated by ~20° twisting of its N and C-terminal lobes (Fig. 4a). The 
structure demonstrates that the binding of G protein and βarr to the same GPCR are not 
mutually exclusive, with both transducers being canonically activated.
Verified by LC-MS/MS analyses, six phosphorylated residues were visualized on the GPCR 
tail, with five of them engaging the active megaplex βarr1 (Fig. 4, and Extended Data Fig. 
10b). These observations further recapitulate cellular data that demonstrate decrease in 
phosphorylation and, by extension, arrestin recruitment to the GPCR after mutating one or a 
series of these phosphorylated residues4,23,29,30. A recent biochemical study showed V2R 
phosphopeptides which contained more phosphorylated residues bind βarr with much higher 
affinity31. Therefore, the presence of multiple phosphorylated residues on the V2T likely 
enhances the affinity of β2V2R–βarr1 interaction and thus contributes to megaplex 
formation. Moreover, our LC-MS/MS results suggest that while some residues are 
phosphorylated independent of receptor stimulation, specific phosphorylation sites are 
necessary to recruit and stabilize βarr1 on the GPCR tail (Extended Data Fig. 10b).
Orientational changes in receptor-bound G proteins have been implicated in downstream 
signaling consequences, as can be observed with previous structures of comparable GPCRs 
in the presence of differing ligands or receptor binders27,28,32,33. In the presence of βarr, the 
Gαs subunit within the megaplex displays a 3° rotation by an axis parallel to the β2V2R–Gs 
contact. Additionally, the Gβγ subunits displays a 3.4° rotation by an axis parallel to the 
membrane, potentially as a consequence of βarr1 binding to the V2T (Figure 3f).
MD experiments reveal a flexible megaplex βarr1 capable of adopting multiple positions in 
relation to the β2V2R–Gs subcomplex, and hints at transient contacts made between 
nonpolar βarr1 edge residues and the membrane. Comparable C-edge loops within visual 
arrestin have also been shown to interact with the lipid bilayer when bound to an active 
rhodopsin22,23. Recently, our group has also demonstrated that the tail conformation of a 
GPCR–βarr complex is capable of signaling, raising an interesting possibility that a 
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megaplex βarr can also signal within internalized compartments by binding to downstream 
effectors11.
We observed an interaction between V2T residues D355 and E356 and βarr1 (presumably at 
K160 and R161) in the megaplex structure. This interaction is analogous to one observed 
between two acidic rhodopsin C-terminal tail residues, D330 and E332, and visual arrestin 
residues R19, K167, and K168. Along with the binding of rhodopsin C-terminal tail residue 
E341 to visual arrestin, these observations suggest that acidic residues, in addition to 
phosphorylated residues, play an important role in the association of arrestin by the C-
terminal tail of a GPCR.
The fact that class B GPCRs primarily signal in a prolonged manner implicates the tail 
conformation in propagating sustained signaling. This is further reinforced by the fact that 
class A GPCRs like the β2AR, which do not tightly associate with βarr, do not signal from 
internalized compartments or do so only weakly9,34. There are two potential ways in which 
βarr may enable a GPCR to continue G protein signaling: (1) by keeping the receptor 
internalized, and (2) by scaffolding free Gβγ to accelerate reassociation of GDP-bound 
Gαs, reforming a Gs heterotrimer that is in close proximity to a receptor-arrestin complex to 
initiate another round of signaling.
βarr seems to serve as a scaffold for Gβγ, and together they have been shown to form a 
complex with a GPCR9,12,35. We have reported that the direct interaction between Gβγ 
subunits and phosphopeptide-bound active βarr1 increases upon Gs activation and separation 
of the Gαs from the Gβγ subunits9. Thus, it is possible that the interface of Gβγ subunits 
that associate with Gαs in the heterotrimeric Gs may interact with βarr1 upon Gs activation 
and Gαs separation. Indeed, currently available structures of Gβγ bound to protein effectors 
all show Gβγ interacting with them on the Gβ interface that normally interacts with Gα, 
consistent with the notion that Gβγ typically binds to other proteins after receptor-mediated 
dissociation from Gα36–38. Such a Gβγ scaffolding role of βarrs may serve to confine the G 
protein near the receptor, resulting in an increased G protein activation rate from internalized 
compartments.
Our structure of the β2V2R–Gs protein–βarr1 megaplex shows an active, ligand-bound 
receptor simultaneously engaging Gs protein by its intracellular core and activating βarr1 via 
six phosphorylated residues in the receptor C-terminal tail. That the receptor is in an active 
conformation, contacts Gs in a canonical fashion, while allowing βarr1 to bind to its 
phosphorylated C-terminal tail points to the GPCR as a master regulator of signaling capable 
of activating G protein in addition to performing βarr-mediated signaling concurrently. 
Finally, our structure provides a biophysical basis for G protein activation and sustained 
signaling within internalized cellular compartments.
Methods
Purification of the T4L-β2V2R–βarr1–Fab30 Complex, Gs Protein, and Protein Stabilizers
Gs protein, Fab30, and Nb32 were purified as previously described11,15,20. The T4L-
β2V2R–βarr1–Fab30 complex is also purified as previously described4. Briefly, Sf9 cells 
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were co-expressed with T4L-β2V2R, untagged bovine βarr1 (1–393), and GRK2-CAAX. 
Sixty-six hours post-infection, cells were stimulated for 30 minutes at 37 °C with 0.5 μM 
BI-167107 to stimulate receptor phosphorylation and complex formation. After harvest, cells 
were resuspended and dounce-homogenized in 20 mM HEPES, 150 mM NaCl, pH 7.4, 100 
nM BI, leupeptin-benzamidine (LB) protease inhibitor. Excess purified Fab30 were added to 
stabilize the complex, and the mixture was stirred for 30 minutes at RT. Subsequently, 
complexes were solubilized with the addition of 0.5% lauryl maltose neopentyl glycol 
(LMNG)/0.05% cholesteryl hemisuccinate (CHS) and the mixture was stirred for an 
additional hour. Cell debris were clarified by centrifugation and solubilized material were 
purified using M1 Anti-Flag resin. Complexes were subjected to a cysteine alkylation 
procedure as previously reported, concentrated using a 100 kDa-cutoff Millipore 
concentrator and loaded onto a size exclusion column (Extended Data Fig. 1)10. The purified 
complexes were flash frozen with glycerol and stored until further use.
Formation of the Megaplex
In order to form megaplexes, the β2V2R–βarr1–Fab30 complex was incubated with excess 
Gs protein, Nb35, and Nb32 at RT for 1 hr in 20 mM HEPES, 150 mM NaCl, pH 7.4, 4 mM 
CaCl2, 0.01% LMNG, and 30 uM BI. Apyrase (25 mU/mL) was then added to the mixture 
and incubated at RT for 1 hr (Extended Data Fig. 1). To pull down megaplexes, M1 beads 
were added with subsequent incubation for an additional hour at RT. The beads were then 
spun down and washed five times with 20 mM HEPES, 150 mM NaCl, pH 7.4, 2 mM 
CaCl2, 0.01% LMNG, and 10 uM BI. Finally, the megaplexes were eluted with buffer 
containing 20 mM HEPES, 100 mM NaCl, pH 7.4, 0.01% LMNG, 30 uM BI, 0.2 mg/ml 
FLAG peptide, 1 mM TCEP, leupeptin-benzamidine protease inhibitor and 5 mM EDTA.
Initial samples were prepared in an identical manner without the use of Nb32.
Cryo-EM Sample Preparation and Data Acquisition
For grid preparation, megaplex samples were used either at a concentration of 0.8 mg/ml or 
diluted to 0.4 mg/ml with the same elution buffer as described above. Three uL of the 
sample was applied to freshly glow-discharged UltrAufoil 0.6/1 300-mesh grids (Quantifoil, 
Großlöbichau, Germany). The grids were prepared on an FEI Vitrobot Mark IV, blotted for 
1.5 sec, and vitrified by plunge freezing into liquid ethane cooled by liquid nitrogen at −180 
°C. Longer blot time consistently yielded dissociated complexes, pointing to a time-
dependent dissociation of the complexes at the air-water interface39. The addition of Nb32 
significantly enhanced the number of intact complexes (Extended Data Fig. 2).
Data acquisition at the Howard Hughes Medical Institute Janelia Research Campus was 
done on an FEI Titan Krios (Janelia Krios 1) operating at 300 kV equipped with a spherical 
aberration corrector, an energy filter (Gatan GIF Quantum), and a post-GIF K2 Summit 
direct electron detector. Images were obtained in super-resolution counting mode with a 
super-resolution pixel size of 0.52Å, which corresponds to a physical pixel size of 1.04 Å. 
An energy slit with a width of 20 eV was used during data collection. Fully automated data 
collection was carried out using the SerialEM software40. Initial data collection and analysis 
showed that intact megaplex particles exhibited preferred orientation (Extended Data Fig. 2). 
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Attempts to alleviate this problem was unsuccessful. Therefore, tilted data collection was 
employed to improve orientational distribution41.
In total, five separate datasets were collected with the stage tilted at 30°,40°, and 45° on 
Janelia Krios 1. For an initial dataset comprising 30° and 40° tilted micrographs (Extended 
Data Fig. 4, dataset 1), the dose rate was set at 8 e−/pixel/s and the total exposure time was 
14 s, resulting in a total dose of 103.5 e−/Å2. With dose fractionation set at 0.2 s/frame, each 
movie series contains 70 frames. For subsequent 40° and 45° tilted data collections 
(Extended Data Fig. 4, datasets 2–5), the dose rate was set at 8 e−/pixel/s and the total 
exposure time was 14.1 s, resulting in a total dose of 104.3 e−/Å2. With dose fractionation 
set at 0.15 s/frame, each movie series contains 94 frames.
All data collected at New York Structural Biology Center (NYSBC) was done on an FEI 
Titan Krios (NYSBC Krios 2) operating at 300 kV equipped with a spherical aberration 
corrector, an energy filter (Gatan GIF Quantum), and a post-GIF K2 Summit direct electron 
detector. Images were obtained in electron counting mode with a physical pixel size of 1.1 
Å. An energy slit with a width of 20 eV was used during data collection. Fully automated 
data collection was carried out using the Leginon software42.
In total, two datasets were collected on NYSBC Krios 2. A dataset that comprises 45° and 
50° tilted micrographs (Extended Data Fig. 4, dataset 6) had a dose rate of 8.65 e−/pixel/s 
and a total exposure time of 14 s, resulting in a total dose of 103.5 e−/Å2. With dose 
fractionation set at 0.2 s/frame, each movie series contains 70 frames. A subsequent dataset 
of 40° tilted micrographs (Extended Data Fig. 4, dataset 7) was collected with a dose rate of 
8.38 e−/pixel/s and a total exposure time of 13.95 s, resulting in a total dose of 96.61 e−/Å2. 
With dose fractionation set at 0.15 s/frame, each movie series contains 93 frames.
Data Processing
All data processing operations were performed with Warp v. 1.0.5, Relion 3.0-beta-2, and 
cryoSPARC v2.4.0 unless otherwise specified43–45. Warp was used for gain correction and 
motion correction of all raw frames, as well as for particle picking and per-particle CTF 
estimation. Subsequently, particles were extracted for processing in cryoSPARC, where each 
dataset was first put through 2D classification in order to remove false positives. Multiple 
rounds of heterogeneous refinement against a megaplex reconstruction and three other decoy 
structures was performed to clean up the dataset (Extended Data Fig. 3).
Cleaned particles from the NYSBC datasets were rescaled to a pixel size of 1.04Å and 
combined with particles from the Janelia datasets, resulting in a total of 476,250 megaplex 
particles. These particles subsequently underwent two rounds of heterogeneous refinement 
against a megaplex reconstruction and three other decoy structures, resulting in 317,529 
particles that made up the megaplex consensus reconstruction (Extended Data Fig. 4, 5). The 
map was sharpened within cryoSPARC using an estimated b-factor of −202.3 Å2.
To obtain a higher resolution reconstruction of the β2V2R–Gs portion, signal subtraction was 
performed in Relion to subtract density corresponding to T4L and the Nb32–V2T–βarr1–
Fab30 portion of the megaplex. The signal subtracted particle stack was further cleaned 
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through one round of cryoSPARC heterogeneous refinement against a segmented β2V2R–Gs 
map and three decoy structures, resulting in 299,893 β2V2R–Gs particles. Finally, these 
particles were refined in cryoSPARC using non-uniform refinement followed by local non-
uniform refinement, resulting in a final reconstruction of the β2V2R–Gs portion at 3.8Å 
(Extended Data Figs. 4,6). The map was sharpened within cryoSPARC using an estimated b-
factor of −133.6 Å2.
As the βarr1–V2T portion (which contains the Nb32–V2T–βarr1–Fab30 portion of the 
megaplex) is much smaller than the β2V2R–Gs portion, we first performed multibody 
refinement within Relion, subtracted the T4L–β2V2R–Gs portion from the particle images, 
and re-centered them on the βarr1–V2T density. These subtracted, re-centered βarr1–V2T 
particles were put through two rounds of cryoSPARC heterogeneous refinement against a 
segmented Nb32–V2T–βarr1–Fab30 map and three decoy structures, resulting in 230,021 
particles. Finally, these particles were refined in cryoSPARC using non-uniform refinement, 
followed by local non-uniform refinement, resulting in a final reconstruction at 4.0Å 
(Extended Data Figs. 4,6). The map was sharpened within cryoSPARC using an estimated b-
factor of −139 Å2.
The signal-subtracted reconstructions were fitted within and resampled on the grid of the 
consensus megaplex reconstruction using the vop resample command within UCSF 
Chimera.
For each reconstruction, gold-standard fourier shell correlation (FSC = 0.143 criterion) was 
determined within cryoSPARC, and local resolution was determined using the program 
MonoRes, implemented within cryoSPARC45,46. Three-dimensional FSC (3D-FSC) to 
assess for directional resolution anisotropy was determined using the 3D-FSC web server 
(https://3dfsc.salk.edu)41. To calculate map-to-model sphericity, the models were converted 
to density maps at 2.08 Å using Chimera. To make the mask, the models were converted to 
density maps at 8 Å using Chimera and binarized using Relion 3 with a soft Gaussian edge 
of 3 pixels. The FSC and 3D-FSC of map to model was calculated between the sharpened 
density maps and the model density map using the 3DFSC server at a FSC threshold of 0.5, 
after applying the aforementioned mask. Finally, map-to-model FSC (FSC = 0.5 criterion) 
was determined using phenix.mtriage47.
Model Building
The β2V2R–Gs and βarr1–V2T portions of the megaplex were modeled using the β2AR–Gs–
Nb35 (PDB: 3SN6) and the V2Rpp–βarr1–Fab30 (PDB: 4JQI) crystal structures as starting 
points, respectively. A homology model of Nb32 was generated using the I-TASSER web 
server48. The crystal structures were first rigidly fitted into their corresponding signal-
subtracted maps in UCSF Chimera, followed by manual adjustments and model building in 
Coot49,50. Atomic models for each subcomplexes were refined against the signal-subtracted 
density map using phenix.real_space_refine with Ramachandran, rotamer, torsion, and 
secondary structure restraints enforced47. Additional modeling and manual adjustments were 
performed in Coot and the modeling statistics were validated using MolProbity51. All 
structural comparisons and figures were made with UCSF Chimera, UCSF ChimeraX, and 
PyMOL (pymol.org)49,52.
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Coarse-grained Molecular Dynamics (MD) Simulations
All MD starting structures were modified from the cryo-EM structure to allow for proper 
receptor placement in a DPPC membrane. The linker (343-ARGGRTPPSLGPQD-355) from 
the end of helix 8 to the C terminal tail of the receptor was modeled in through PyMOL 
(pymol.org) and clashes between side chains were minimized using PyMOL sculpting tool. 
These structures was then embedded in a 30 nm DPPC lipid bilayer and set up for martini 
coarse graining using the CHARMM_GUI website53,54. All MD calculations were 
performed using the SBgrid software package with GROMACS 2018.1 at 303K55. The 
complex was minimized in 10,000 steps and subjected to 5 rounds of equilibration, each of 1 
ns, to stabilize the system with a time interval of 0.02 ps between calculations. 30 
nanoseconds of production were run on each MD to ensure stability of the complex. All final 
MD structures were visualized and analyzed through VMD and PyMOL56.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
All solvents are of MS-grade and purchased from Fisher Scientific, unless otherwise 
specified. Gel-bands were cut into small pieces of approximately 1mm3 using a scalpel and 
destained, reduced and alkylated as previously described57. Digestion was carried out at 
37°C overnight using a combination of sequencing grade trypsin (Promega) and 
endopeptidase LysC (Wako Chemicals). Two iterations of peptide extraction were performed 
using 70% acetonitrile, 5% formic acid in water and peptides were dried using a vacuum 
centrifuge (Savant).
Liquid chromatography was performed on a Dionex 3000 Ultimate HPLC equipped with a 
NCS3500RS nano- and microflow pump (Dionex). Peptides were loaded onto a 100 
μm*20mm Acclaim PepMap C18 trap column (Thermo Scientific) at 3μL/min. Solvent A 
consisted of 0.1 % formic acid in water and solvent B consisted of 0.1% formic acid, 80% 
acetonitrile in water. Separation was achieved using a 75μm*120mm pulled-emitter 
nanocolumn (Nikkyo Technos). Solvent B went from 1% – 38% over 70 minutes followed 
by a sharp 1-minute increase to 90% where it was kept for 13 minutes. Peptides were 
analyzed using a Q-Exactive HF mass spectrometer (Thermo Scientific) operating in positive 
ion mode. For the data-dependent analyses, spectra were recorded in data dependent 
acquisition (DDA) mode, selecting the 20 most abundant ions for fragmentation within each 
duty cycle. MS1 resolution was set to 60 000 and an MS2 resolution was set to 30 000. AGC 
targets of 3e6 (MS1) and 2e5 (MS2) were applied.
A parallel reaction monitoring (PRM) method was designed to target two peptides from the 
C-terminus which were found to be phosphorylated from the DDA experiment. The targets 
were TPPSLGPQDESCTTASSSLAK with 0–3 phosphorylations and 
GRTPPSLGPQDESCTTASSSLAK with 0–4 phosphorylations.
Data was searched using MaxQuant v. 1.6.258. Default settings were applied. 
Phosphorylation of S and T and oxidation of M were applied as variable modifications. 
Carbamidomethylation of C was applied as a static modification. A maximum of 8 possible 
modifications per peptide was allowed. Match between runs was enabled. Collapsed 
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phosphosite information was exported, from which the localization probabilities for 
phosphorylations at individual residues could be determined59.
MS1 peak areas were extracted using Skyline v. 4.1.0.1816960. Peak areas from the two 
peptide targets were collapsed to provide an intensity for the region of interest with varying 
number phosphorylations. Intensity values of the C-terminal region were normalized based 
on all identified peptides from the protein.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository with the dataset identifier PXD015298.
Real-time cAMP measurement
Previously described βarr1/βarr2/β2AR triple-knockout HEK293 cells were transiently co-
transfected with plasmids encoding the bioluminescence resonance energy transfer (BRET)-
based CAMYEL cAMP biosensor (YFP-Epac-Rluc) and either β2V2R, β2V2R–βarr1, 
β2V2R–βarr1, or pcDNA3.1(+) mock control11. Twenty-four hours after transfection, the 
cells were plated in poly-D-lysine coated white 96-well plates (Coring, USA) and incubated 
overnight. Forty-eight hours after transfection, the cells were washed and placed in assay 
buffer (HBSS + 10 mM HEPES, pH 7.4) at 37 °C for 30 min. Cells were loaded with 5 μM 
luciferase substrate coelenterazine H for 5 min and BRET was detected through Rluc8 
luminescence (480 nm) and YFP fluorescence (530 nm) measurements using a CLARIOstar 
Plus plate reader (BMG Labtech). After a 2-min basal period, cells were challenged with 1 
μM BI-167107. Forskolin (10 μM) was used as a positive control, and regular assay buffer as 
a negative/baseline control. All data was subsequently normalized to the 10 μM Forskolin 
control. Data represents mean ± S.E.M. of four independent experiments for the β2V2R–
βarr1 and β2V2R–βarr2 conditions and of three independent experiments for the β2V2R 
condition. Ordinary one-way ANOVA with Holm-Sidak’s multiple comparison post-hoc test 
was performed to determine statistical significance between mock control and the β2V2R or 
β2V2R–βarr1/2 conditions.
Further information on experimental design is available in the Nature Research Reporting 
Summary linked to this article.
Data Availability
Cryo-EM maps corresponding to the consensus megaplex reconstruction as well as the 
signal-subtracted β2V2R–Gs and βarr1–V2T subcomplexes have been deposited in the 
Electron Microscopy Data Bank (EMDB) with accession codes EMD-9377, EMD-9376, and 
EMD-9375, respectively. Atomic coordinates for the β2V2R–Gs and βarr1–V2T 
subcomplexes have been deposited in the Protein Data Bank (PDB) with accession codes 
PDB-6NI3 and PDB-6NI2, respectively. The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the 
dataset identifier PXD015298. Source data for Extended Data Figures 1c and 1d are 
available with the paper online. Other data that support the findings of this study are 
available from the corresponding authors upon request.
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Extended Data
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Extended Data Fig. 1: Sample preparation and purification of the megaplex.
a, Schematic illustration of the purification and in vitro formation procedure of the 
megaplex. b, Size exclusion chromatogram of the precursor β2V2R–βarr1–Fab30 complex. 
c, SDS-PAGE gel of the β2V2R–βarr1–Fab30 complex after purification by size exclusion 
chromatography. d, SDS-PAGE gel of the megaplex after in vitro formation and M1 anti-
Flag purification. For c-d, M denotes molecular weight (kDa) marker. Uncropped gel images 
for Extended Data Fig. 1c,d are provided as Source Data.
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Extended Data Fig. 2: Nanobody 32 (Nb32) stabilizes the megaplex.
a, Representative micrograph and 2D class averages of megaplex samples prepared without 
nanobody 32 (Nb32), displaying a small percentage of megaplexes. b, Same as in a, but with 
a megaplex sample prepared with Nb32.
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Extended Data Fig. 3: A procedure utilizing Warp and cryoSPARC for initial data processing 
and cleaning of one representative dataset (Dataset 2).
The same procedure was used on all dataset.
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Extended Data Fig. 4: 
Data processing workflow for all datasets of the megaplex.
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Extended Data Fig. 5: Megaplex consensus reconstruction.
a, Representative 2D class averages of the consensus megaplex reconstruction. b-c, The 
megaplex reconstruction is shown at high (0.115) threshold (b), and low (0.05) threshold (c). 
The T4L and flexible portion of the V2T appears at a lower threshold. The atomic models of 
the components, derived from signal subtracted reconstructions, are fitted to the consensus 
reconstruction. Densities for the flexible V2T and steric clash between the β2V2R and Nb32 
are denoted by black circles.
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Extended Data Fig. 6: Orientational distribution and resolution measurements of the megaplex.
a-d, orientational distribution (a), FSC curves indicating overall resolution (FSC = 0.143) 
(b), 3D-FSC to assess directional resolution anisotropy (c), and local resolution 
measurements (d) of the megaplex consensus reconstruction. e-j, orientational distribution 
(e), FSC curves indicating overall resolution (FSC = 0.143) (f), 3D-FSC to assess directional 
resolution anisotropy (g), map-to-model FSC and sphericity (h), local resolution 
measurements (i), and map-to-model FSC curve (j) of the β2V2R–Gs reconstruction. k-p, 
same as e-j, but for the βarr1–V2T reconstruction.
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Extended Data Fig. 7: Representative densities in black mesh of various protein components.
Representative densities, from the 3.8Å β2V2R–Gs and 4.0Å βarr1–V2T structures, of the 
β2V2R, Gs subunits, and βarr1.
Nguyen et al. Page 22
Nat Struct Mol Biol. Author manuscript; available in PMC 2020 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 8: Representative density of the β2V2R–Gs portion of the megaplex, and 
comparison against other active β2AR structures.
a, Comparison of the binding pose of BI-167107 (BI) in the megaplex against three other 
available BI-bound β2AR structures. BI is colored green. b, Representative density showing 
contacts between the β2V2R and Gs in the megaplex. c, The BI binding pocket within the 
megaplex, accompanied by EM density for all residues within 5 Å of the ligand.
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Extended Data Fig. 9: Interaction between Fab30, V2T and protein stabilizers.
a-b, Interface between βarr1 and V2T with either Nb32 (a) or Fab30 (b). Interface residues 
are labeled.
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Extended Data Fig. 10: Verification of observed phosphorylation sites on the V2T.
a, Cryo-EM density for the six phosphorylated residues on the V2T. b, Localization 
probabilities of eight potential sites of phosphorylation on the V2T assessed by LC-MS/MS. 
A trypsin-digested fragment of the V2T is displayed. Bolded residues are phosphorylation 
sites observed in the cryo-EM map. Residues in red were not observed in the map, and 
yellow-highlighted residues were phosphorylated in both unstimulated and BI-stimulated 
receptors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Schematic illustration of the mechanism of sustained signaling through the formation of 
endosomal class B GPCR–G protein–βarr megacomplexes.
Binding of β-arrestin (βarr) to a GRK-phosphorylated GPCR tail (leaving the receptor 
intracellular core open) and subsequent receptor internalization allows for further G protein 
binding, forming a megaplex (black box). The megaplex continues to activate G protein, 
leading to sustained endosomal cAMP generation.
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Fig. 2. Cryo-EM structure of a β2V2R–Gs–βarr1 megaplex.
a, Composite cryo-EM density map of the megaplex reconstruction fitted into a transparent 
envelope of the megaplex consensus structure. b, Same as in a, but with protein stabilizers 
(Nb35, Nb32, and Fab30) and consensus reconstruction removed. Red dashed lines indicate 
the flexible C-terminal tail connecting βarr1 to the receptor.
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Fig. 3. Structure and interactions of the β2V2R–Gs portion of the megaplex
a, Orthogonal views of the density map and model for the β2V2R–Gs portion of the 
megaplex. Small top image orients the β2V2R–Gs subcomplex in relation to the megaplex 
consensus structure. b, Intracellular view of the superimposition between the megaplex 
β2V2R and the inactive, carazolol-bound β2AR (PDB: 2RH1). Blue arrows indicate 
movements in transmembrane helices (TMs) 3,5,6 and 7 and their magnitudes. c, 
Intracellular view of the superimposition between the megaplex β2V2R and the Gs-bound 
β2AR (PDB: 3SN6). d, Ligand-binding pocket of the β2V2R, with density for the agonist 
BI-167107 (BI-167107, green) in mesh. e, Interaction of the α5-helix of Gαs with 
hydrophobic residues on TM5 and TM6, and with polar residues between TM3 and TM5 of 
the β2V2R. β2V2R residues are labeled in black for d and e. f, Structural comparison of the 
β2AR–Gs complex (pink, PDB: 3SN6) against the β2V2R–Gs portion of the megaplex, both 
aligned by their receptors. Curved arrows indicate 3° rotation of Gαs around an axis parallel 
to the β2V2R-α5 helix contact and 3.4° rotation of Gβγ around an axis parallel to the 
plasma membrane seen in the megaplex.
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Fig. 4. Structure and interactions of the βarr1–V2T portion of the megaplex.
a, Density map and model for the megaplex βarr1–V2T. Mesh delineates density for the 
V2T. Small top image orients the βarr1–V2T subcomplex in relation to the megaplex 
consensus structure. b,c, Regions of the V2T with phosphorylated residues pS357, pT359, 
pT360 (b) and pS362, pS363, and pS364 (c) interacting with positively charged residues on 
βarr1, which are colored in green and labeled in blue.
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Fig. 5. Comparison of the megaplex βarr1–V2T to the V2Rpp–βarr1–Fab30 and rhodopsin–
visual arrestin crystal structures.
a, Superimposition between the βarr1–V2T (megaplex) and the V2Rpp–βarr1–Fab30 crystal 
structure. Inset shows interaction between pT347 and pS350 of the V2Rpp with residues 
near the finger loop region of βarr1. Red and yellow arrows delineate the differing path of 
the V2T and V2Rpp, respectively. b, Alignment between βarr1–V2T (megaplex) and the 
rhodopsin–visual arrestin crystal structure. For clarity, only βarr1 of the megaplex is shown 
in a and b.
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Figure 6. The megaplex within a membrane environment.
a, Orthogonal views of three modeled megaplex structures for molecular dynamics (MD) 
simulations with differing βarr1–V2T positions, aligned by their β2V2R–Gs region. b, 
Coarse-grained MD models of the three structures, aligned by their β2V2R–Gs region at 10 
ns increments. Black circles denote transient contact between βarr1 residues and the lipid 
bilayer. c, Real-time cAMP measurement of BI-stimulated β2V2R or β2V2R–βarr1/2 in 
β2AR/βarr1/βarr2 triple knock-out HEK293 cells, expressed as percentages of 10 μM 
Forskolin control. Data represents mean ± S.E.M. of four independent experiments for the 
β2V2R–βarr1 and β2V2R–βarr2 conditions and of three independent experiments for the 
β2V2R condition. Ordinary one-way ANOVA with Holm-Sidak’s multiple comparison post-
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hoc test was performed to determine statistical significance between mock control and the 
β2V2R or β2V2R–βarr1/2 conditions (****P < 0.0001).
Nguyen et al. Page 36
Nat Struct Mol Biol. Author manuscript; available in PMC 2020 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Nguyen et al. Page 37
Table 1.
Cryo-EM data collection, refinement and validation statistics
Megaplex Consensus 
Reconstruction 
(EMD-9377)
β2V2R–Gs (EMD-9376, PDB 
6NI3)
βarr1–V2T (EMD-9375, PDB 
6NI2)
Data collection and processing
Magnification 105,000 105,000 105,000
Voltage (kV) 300 300 300
Electron exposure (e−/Å2) 104.3 104.3 104.3
Defocus range (μm) 1.0–3.5 1.0–3.5 1.0–3.5
Pixel size (Å) 1.04 1.04 1.04
Symmetry imposed C1 C1 C1
Initial particle images (no.) 8.15 million 8.15 million 8.15 million
Final particle images (no.) 317,529 299,893 230,021
Map resolution (Å) 4.8 3.8 4.0
 FSC threshold 0.143 0.143 0.143
Map resolution range (Å) 7–12 3.5–7 3.5–7
Refinement
Initial model used (PDB code) 3SN6 4JQI
Model resolution (Å) 4.15 4.37
 FSC threshold 0.5 0.5
Model resolution range (Å)
Map sharpening B factor (Å2) −202.3 −133.6 −139.0
Model composition
 Nonhydrogen atoms 8136 5381
 Protein residues 1043 704
 Ligands 1 0
B factors (Å2)
 Protein 83.75 131.66
 Ligand 74.16
R.m.s. deviations
 Bond lengths (Å) 0.01 0.009
 Bond angles (°) 1.197 1.297
Validation
MolProbity score 1.6 1.81
Clashscore 4.67 6.6
Poor rotamers (%) 0.23 0
Ramachandran plot
 Favored (%) 94.83 93.11
 Allowed (%) 5.17 6.74
 Disallowed (%) 0 0.15
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